Page 19 - Wondergem
P. 19
Table 1: studies with separate analysis of outcome in TFL year of nr (%of
1,2,3
2 2
2
2 n/a
1
n/a 2
2
2 n/a 2
2
1 2
2
2 n/a
n/a
(CR/PR)%
40
56,5 (26,1/30,4)
66 (13/53) 40% (65/17)
100 (50/50)
50 (13/38) 56 (33/22)
33 (0/33)
45 (21/24) 87,5 (25/62,5) ng
25 (0/25)
100 (100/0) 70%
100 (67/33)
ng ng
94
1
Introduction and scope of this thesis
Therapy
author
TFL patients
RS/P
U/R
Phase
therapy detail
ORR
OS
chemotherapy
publication Churpek 2013 Czuczman 2011
Friedberg 2006 Friedberg 2013 Guirguis 2014
Ogura 2011
Vose 2013 Wang 2013
Wiernik 2008 Witzig 2011 Aydin 2007 Jermann 2003
Buchegger 2011
Roy 2013 Briones 2014
Hohloch 2011
Krishnan 2008
Wondergem 2012
Ban-Hoef fen 2012
total) 5(10) 23(70)
15(20) 5(10) 60(19)
2(22)
10(11) 9(20)
3(6) 33(15) 8(40) 18(36)
4(25)
1 8(27)
6(38)
4(10) 24(100)
18(100)
P P
P P R
P
RS P
P P RS P
P
P P
P
P RS
RS
R R
R R U
R
R R
R R R R
R
R R
R
R U
R
ixabepilone lenalidomide
bendamustine alisertib R-CHOP
R-bendamustine
lenalidomide R-lenalidomide
lenalidomide lenalidomide R-ASHAP R-EPOCH
I131-tositumomab
RIT bortezomib Zevalin BEAM
I131-rituximab- BEAM
Zevalin BEAM Zevalin BEAM
AuSCT BEAM/ BEAC/CyTBI
ng
med 12.8 m
ng ng
5yr 66%
ng
ng
med 11.5 m
ng
ng
ng
med 12.4m
2yr25%
ng
3yrOS 66%
4yr 100%
ng
2yr 100%
2yr82%
el Helw 2000
4(7)
P
R
2
vincristine, epirubicine, dexamethasone
100 (25/75)
2yr75%
Kraut 2002
8(28)
P
R
2
topotecan
12,5
ng
Redman 1992
3(5)
P
R
2
fludarabine phosphate
33 (0/33)
ng
intensification with chemotherapy
radioimmunotherapy
Rodriguez 1995
14(15)
P
R
2
MINE-ESHAP
61 (36/25)
2yr 30%
Davies 2004
7(17)
P
R
2
I131-tositumomab
71 (28/43)
ng
Kaminski 2000
14(24)
P
R
1,2
I131-tositumomab
79 (50/29)
ng
Kaminski 2001
23(38)
P
R
3
I131-tositumomab
39 (13/26)
ng
Kaminski 1996
8(23)
P
R
1
I131-tositumomab
74 (38/38)
ng
Linden 2002
2(18)
P
R
2
I131-labelled anti CD22
100 (50/50)
1yr50%
Vose 2000
10(21)
P
U+R
2
I131-tositumomab
60 (50/10)
ng
Witzig 2002
13(9)
P
R
3
Zevalin
56armA,75 arm B
ng
radioimmunotherapy and AuSCT
AuSCT
Bastion 1995
16(27)
RS
R
n/a
various
99(77/15)
2yr63%
Berglund 2000
11(50)
RS
R
n/a
various
100(77/23)
2yr81%
Blystadt 1999
10(40)
P
R
2
TBI purged
100(84/16)
5yr 40%
Cao 2001
17(18)
RS
R
n/a
Cy-eto-TBI/B
93 (64/29)
4yr 50%
Carraciolo 1993
3(21)
P
R
2
HDT TBI-Mel
100(100/0)
med 29m
17
